Literature DB >> 19237565

Crystal structure of human CDK4 in complex with a D-type cyclin.

Philip J Day1, Anne Cleasby, Ian J Tickle, Marc O'Reilly, Joe E Coyle, Finn P Holding, Rachel L McMenamin, Jeff Yon, Rajiv Chopra, Christoph Lengauer, Harren Jhoti.   

Abstract

The cyclin D1-cyclin-dependent kinase 4 (CDK4) complex is a key regulator of the transition through the G(1) phase of the cell cycle. Among the cyclin/CDKs, CDK4 and cyclin D1 are the most frequently activated by somatic genetic alterations in multiple tumor types. Thus, aberrant regulation of the CDK4/cyclin D1 pathway plays an essential role in oncogenesis; hence, CDK4 is a genetically validated therapeutic target. Although X-ray crystallographic structures have been determined for various CDK/cyclin complexes, CDK4/cyclin D1 has remained highly refractory to structure determination. Here, we report the crystal structure of CDK4 in complex with cyclin D1 at a resolution of 2.3 A. Although CDK4 is bound to cyclin D1 and has a phosphorylated T-loop, CDK4 is in an inactive conformation and the conformation of the heterodimer diverges from the previously known CDK/cyclin binary complexes, which suggests a unique mechanism for the process of CDK4 regulation and activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237565      PMCID: PMC2657441          DOI: 10.1073/pnas.0809645106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Characterization of 4 mantle cell lymphoma cell lines.

Authors:  Hesham M Amin; Timothy J McDonnell; L Jeffrey Medeiros; Georgios Z Rassidakis; Vasiliki Leventaki; Sean L O'Connor; Michael J Keating; Raymond Lai
Journal:  Arch Pathol Lab Med       Date:  2003-04       Impact factor: 5.534

Review 2.  Cyclin D1 in breast cancer pathogenesis.

Authors:  Andrew Arnold; Alexandros Papanikolaou
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

3.  Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.

Authors:  Mark W Landis; Basil S Pawlyk; Tiansen Li; Piotr Sicinski; Philip W Hinds
Journal:  Cancer Cell       Date:  2006-01       Impact factor: 31.743

4.  Purification, characterization, and kinetic mechanism of cyclin D1. CDK4, a major target for cell cycle regulation.

Authors:  A K Konstantinidis; R Radhakrishnan; F Gu; R N Rao; W K Yeh
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

5.  Structural basis for CDK6 activation by a virus-encoded cyclin.

Authors:  Ursula Schulze-Gahmen; Sung-Hou Kim
Journal:  Nat Struct Biol       Date:  2002-03

6.  A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.

Authors:  W Pan; S Cox; R H Hoess; R H Grafström
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

7.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

Review 8.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

9.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

10.  Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.

Authors:  D H Brotherton; V Dhanaraj; S Wick; L Brizuela; P J Domaille; E Volyanik; X Xu; E Parisini; B O Smith; S J Archer; M Serrano; S L Brenner; T L Blundell; E D Laue
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

View more
  85 in total

1.  Molecular mechanism by which palmitate inhibits PKR autophosphorylation.

Authors:  Hyunju Cho; Shayantani Mukherjee; Pratheeba Palasuberniam; Lisa Pillow; Betul Bilgin; Catherine Nezich; S Patrick Walton; Michael Feig; Christina Chan
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

Review 2.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

4.  Astex shapes CDK4/6 inhibitor for approval.

Authors:  Mark Peplow
Journal:  Nat Biotechnol       Date:  2017-05-09       Impact factor: 54.908

5.  CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells.

Authors:  Huabo Chen; Xiaowei Xu; Guopeng Wang; Boyan Zhang; Gang Wang; Guangwei Xin; Junjun Liu; Qing Jiang; Hongyin Zhang; Chuanmao Zhang
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

6.  The structure of CDK4/cyclin D3 has implications for models of CDK activation.

Authors:  T Takaki; A Echalier; N R Brown; T Hunt; J A Endicott; M E M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 7.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

8.  Cyclin-dependent kinase 4 may be expressed as multiple proteins and have functions that are independent of binding to CCND and RB and occur at the S and G 2/M phases of the cell cycle.

Authors:  Yuan Sun; Xiaomin Lou; Min Yang; Chengfu Yuan; Ling Ma; Bing-Kun Xie; Jian-Min Wu; Wei Yang; Steven Xj Shen; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2013-09-24       Impact factor: 4.534

Review 9.  Structure-based discovery of cyclin-dependent protein kinase inhibitors.

Authors:  Mathew P Martin; Jane A Endicott; Martin E M Noble
Journal:  Essays Biochem       Date:  2017-11-08       Impact factor: 8.000

10.  Edgetic perturbation models of human inherited disorders.

Authors:  Quan Zhong; Nicolas Simonis; Qian-Ru Li; Benoit Charloteaux; Fabien Heuze; Niels Klitgord; Stanley Tam; Haiyuan Yu; Kavitha Venkatesan; Danny Mou; Venus Swearingen; Muhammed A Yildirim; Han Yan; Amélie Dricot; David Szeto; Chenwei Lin; Tong Hao; Changyu Fan; Stuart Milstein; Denis Dupuy; Robert Brasseur; David E Hill; Michael E Cusick; Marc Vidal
Journal:  Mol Syst Biol       Date:  2009-11-03       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.